HCPCS Level II code J1729 denotes a 10 mg unit of hydroxyprogesterone caproate administered by injection. Nationally, this injectable progestin is used in clinical contexts where parenteral progesterone therapy is indicated, and accurate coding of J1729 is important for claims processing, benefit determination, and drug utilization tracking. Payers commonly encountered in national analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

This publication provides a concise overview of the clinical and billing context for J1729, outlines payer considerations, and highlights benchmarks and policy-relevant points readers should expect to see. Topics covered include typical sites of service (outpatient clinics and physician offices), service line implications for drug administration billing, and payer coverage patterns. The report also summarizes common modifiers and coding practices where available and identifies areas where input data were not provided.

Readers will gain a clear understanding of what J1729 represents, which payers to consider for national billing contexts, and which aspects of reimbursement and documentation commonly influence claim adjudication. Data not available in the input are noted where applicable.